19 (7):582-590 Corresponding authors: Suowen Xu, PhD or Jianping Weng, MD, PhD, E-mail: sxu1984
Updated July 2026 The Ozempic and GLP-1 gastroparesis lawsuits involve claims that manufacturers of GLP-1 medications such as Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity, Zepbound, and Saxenda failed to adequately warn patients and doctors about the potential risk of developing gastroparesis (i.e., stomach paralysis or delayed gastric emptying), a serious gastrointestinal injury that can cause persistent nausea, vomiting, abdominal pain, bloating, dehydration, malnutrition, hospitalization, or the need for feeding tubes or other invasive treatment
A Certificate of Analysis (COA) is included with each order, documenting the HPLC chromatogram, mass spectrometry data, and batch-specific test results
"So, we had to quantify this evidence to show that it stemmed from the FDA approval and how to contain the risk." He added that the next step is better public education and that the long-term safety of the drug for millions of new users remains an active area of research
That is generally desirable for tissue repair, but could theoretically influence tumor environments